ArticleFrontiers in genetics2025
Multi-omics pan-cancer analysis reveals the diagnostic and prognostic value of C8orf76, with experimental validation of its impact on lung adenocarcinoma cell proliferation.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The tumor promoter role and molecular mechanism of C8orf76/CALB2 axis in clear cell renal cell carcinoma.iScience · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chromosome 8 open reading frame 76 (C8orf76) is a nuclear protein-encoding gene, has received limited attention in current study. Multi-omics pan-cancer analysis focused on the diagnosis, prognosis, immune cell infiltration, methylation, and anti-cancer drug sensitivity remains an enigma. The effect of C8orf76 on lung adenocarcinoma (LUAD) is unknown. Methods: Multi-omics pan-cancer analysis by utilizing datasets including UALCAN, TIMER 2.0, Human Protein Atlas (HPA), The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), cBioPortal, Gene Expression Profiling Interactive Analysis (GEPIA), OncoDB, and MethSurv datasets, were conducted to analyze C8orf76 across 33 cancer types. Furthermore, differential R packages were uesd for an in-depth analysis of C8orf76. The correlation between C8orf76 expression and diagnostic, prognosis, genetic alteration, mRNA modification, DNA methylation, lncRNA-miRNA-C8orf76 regulatory network, immune cell infiltration, and anti-tumor drugs response were explored to evaluate the potential roles of C8orf76. Most importantly, experiments including quantitative polymerase chain reaction (qPCR), RNA interference (RNAi), Western blotting (WB), and Edu staining, were performed for experimental verification. Results: It was noted that the C8orf76 expression was markedly elevated across multiple tumor types. Moreover, C8orf76 showed potential as a diagnostic and prognostic biomarker. Besides, it was confirmed that the expression of C8orf76 was related to DNA methylation, mRNA modification, and the infiltration of immune cells. The lncRNA-miRNA-C8orf76 network was established in the study of LUAD. Experimental validation in LUAD A549 cells demonstrated that the knockdown of C8orf76 significantly inhibited cell proliferation in LUAD. Conclusion: The present study is the first to report that the multi-omics pan-cancer analysis predicts C8orf76 as a promising target in cancer prognosis, diagnosis, immunology, and chemotherapy, highlighting its influence on cell proliferation in LUAD with experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.